About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Psychiatry, Mental Health and Addictions Research Group at the Vall d'Hebron Research Institute is a multidisciplinary team that over the past 13 years has focused its scientific activity on the research (both nationally and internationally) of clinical, therapeutic and etiopathogenic aspects of:
At international level, it participates and/or coordinates several European projects of great repercussion in the area of mental health. At national level, it is part of the CIBERSAM (Centre for Biomedical Research in Mental Health Network) together with other leading groups, conducting research of excellence.
PMID: 38044223 Journal: Schizophrenia Research Year: 2023 Reference: Schizophr Res. 2023 Dec 2:S0920-9964(23)00423-1. doi: 10.1016/j.schres.2023.11.011. Impact factor: Publication type: Paper in international publication Authors: Aguilar, Eduardo J; Amoretti, Silvia; Bernardo, Miquel; Berrocoso, Esther; Cuesta, Manuel J; Escarti, Maria J; Garcia-Marti, Gracian; Gonzalez-Pinto, Ana; Ibanez, Angela; Janssen, Joost et al. DOI: 10.1016/j.schres.2023.11.011
PMID: 38086222 Journal: EUROPEAN NEUROPSYCHOPHARMACOLOGY Year: 2023 Reference: Eur Neuropsychopharmacol. 2023 Dec 11;79:32-37. doi: 10.1016/j.euroneuro.2023.10.004. Impact factor: Publication type: Paper in international publication Authors: Alfonso, Miqueu; Amoretti, Silvia; Anmella, Gerard; Arranz, Belen; Bernardo, Miquel; Dal Santo, Francesco; Garcia-Portilla, Maria Paz; Gonzalez-Blanco, Leticia; Hernandez, Carla; Marin Alcaraz, Lorena et al. DOI: 10.1016/j.euroneuro.2023.10.004
PMID: 33495110 Journal: EUROPEAN NEUROPSYCHOPHARMACOLOGY Year: 2021 Reference: Eur Neuropsychopharmacol. 2021 Mar;44:1-13. doi: 10.1016/j.euroneuro.2021.01.002. Epub 2021 Jan 23. Impact factor: 4.6 Publication type: Review in international publication Authors: Pujol-Gualdo, Natalia, Ramos-Quiroga, Josep Antoni, Ribases, Marta, Soler Artigas, Maria, Sanchez-Mora, Cristina et al. DOI: 10.1016/j.euroneuro.2021.01.002
PMID: 33456050 Journal: MOLECULAR PSYCHIATRY Year: 2021 Reference: Mol Psychiatry. 2021 Jun;26(6):2101-2110. doi: 10.1038/s41380-020-01002-z. Epub 2021 Jan 17. Impact factor: 15.992 Publication type: Paper in international publication Authors: Rovira, Paula, Andreassen, Ole, Buitelaar, Jan K, Ching, Christopher R K, Franke, Barbara, Hoogman, Martine, Jahanshad, Neda, McDonald, Carrie, Schmaal, Lianne, Sisodiya, Sanjay M et al. DOI: 10.1038/s41380-020-01002-z
PMID: 33436129 Journal: PSYCHOLOGICAL MEDICINE Year: 2021 Reference: Psychol Med. 2021 Jan 13:1-11. doi: 10.1017/S0033291720005115. Impact factor: 7.723 Publication type: Paper in international publication Authors: Bosch, Rosa, Pagerols, Mireia, Rivas, Cristina, Sixto, Laura, Bricolle, Laura, Espanol-Martin, Gemma, Prat, Raquel, Ramos-Quiroga, Josep A, Casas, Miquel et al. DOI: 10.1017/S0033291720005115
Irritability in ADHD and BDP is an understudied symptom that has a major impact on patients' quality of life and may even increase the risk of suicide.
These results reinforce the need for more individualized attention to address educational needs from an early stage.
On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.
